journal article
LitStream Collection
Home
2017 memo - Magazine of European Medical Oncology
doi: 10.1007/s12254-017-0340-6
At the last meeting of the American Society of Hematology (ASH), data on first-line treatment with obinutuzumab in indolent lymphoma, as well as promising data on the long-term observation of chronic lymphocytic leukemia (CLL) patients treated with ibrutinib, were presented.
2017 memo - Magazine of European Medical Oncology
doi: 10.1007/s12254-017-0330-8
For heterogeneous myelodysplastic syndromes (MDS), patient management is still a challenge. Despite the progress achieved in recent years, there is need for improvement at least for specific situations such as failure of hypomethylating agents or in patients with thrombocytopenia or with anemia failing erythropoiesis stimulating agents. This review covers studies for MDS presented at the American Society of Hematology (ASH) 2016 annual meeting. New treatment approaches, for which results from phase 1/2 studies were reported, will now move into phase 3 and hopefully into clinical practice in the future. Choosing the right agent and individualizing treatment will be the next challenges.
2017 memo - Magazine of European Medical Oncology
doi: 10.1007/s12254-017-0337-1
Allogeneic hematopoietic stem cell transplantation (allo HSCT) offers a potentially curative approach for acute myeloid leukemia (AML) with intermediate or adverse risk according to the recently published European Leukemia Network (ELN) guidelines. As outcome might be reduced by graft-versus-host disease (GvHD) or infectious complications, tools for early detection of GvHD are warranted. In contrast, autologous stem cell transplantation (ASCT) represents a relatively safe therapeutic approach. However, further improvement can be observed by the introduction of maintenance therapy after single ASCT, e. g., with lenalidomide or rituximab.
2017 memo - Magazine of European Medical Oncology
doi: 10.1007/s12254-017-0332-6pmid: 28725274
Amyloidosis is a rare but life-threatening protein misfolding disease. The early diagnosis and enrollment of patients into multicentre trials is of great importance, as is the need for intensive collaboration between multiple medical departments and experienced specialists. In the following review, the most interesting abstracts from the annual American Society of Hematology (ASH) meeting in 2016 are presented. The topics include the limitations of established biomarkers in risk assessment and response evaluation, the introduction of a new biomarker, the comparison of different treatment sequences and the efficacy of a multiple drug regimen in light-chain (AL) amyloidosis.
Feistritzer, Clemens; Mosheimer, Birgit
2017 memo - Magazine of European Medical Oncology
doi: 10.1007/s12254-017-0339-zpmid: 28725275
During the annual meeting of the American Society of Hematology (ASH) in San Diego/California, novel developments in the field of hemostaseology were presented. Alternative treatment strategies besides factor replacement were discussed for patients with hemophilia. One of the highlights of the meeting in this year’s plenary session was the presentation of successful adeno-associated virus mediated gene transfer in patients with hemophilia B leading to sustained elevation of factor IX:C (FIX:c). Other alternative treatment approaches in patients with hemophilia A may include bispecific antibodies mimicking factor VIIIa (FVIIIa) activity or disrupting anticoagulant proteins. Focusing on anticoagulation, data on the use of direct oral anticoagulants (DOACs) in cancer patients with atrial fibrillation as well as treatment of superficial vein thrombosis with rivaroxaban were presented. In this short review, we try to highlight the most important presentations during the ASH meeting 2016.
Bolomsky, Arnold; Ludwig, Heinz
2017 memo - Magazine of European Medical Oncology
doi: 10.1007/s12254-017-0338-0
Treatment of high-risk patients is a major challenge in multiple myeloma (MM). Median survival rates of these patients remain poor at about 2 years and there were no major improvements with the introduction of immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs). This resulted in a remarkable discrepancy in the treatment results of MM, with a significant proportion of patients achieving long-term progression-free survival of >10 years (or even cure) while in patients with aggressive disease no or only minor improvements have been achieved. Current consensus statements define high-risk based on International Staging System (ISS) stage III plus the presence of cytogenetic aberrations (t(4;14) and/or del17p) and/or high lactate dehydrogenase (LDH). Regarding the treatment of high-risk patients, autologous stem cell transplantation remains the standard of care in transplant-eligible candidates. However, there is an unmet need for novel therapeutic strategies to overcome the limitations of current treatment modalities. Hence, efforts to study high-risk disease in MM were recently intensified. The ongoing search for new treatment strategies and drug targets is also reflected by the growing number of studies investigating high-risk disease. This short review aims to provide an overview about the current research landscape and recent progress in high-risk MM based on selected abstracts of the ASH 2016 meeting.
Suppan, Christoph; Balic, Marija
2017 memo - Magazine of European Medical Oncology
doi: 10.1007/s12254-017-0328-2pmid: 28725276
Developments in early breast cancer presented at the 2016 San Antonio Breast Cancer Symposium included important studies on extending adjuvant endocrine therapy with aromatase inhibitors, the role of bisphosphonates, and evidence for molecular prognostic factors and circulating tumor cells in early stage breast cancer patients.
Showing 1 to 10 of 16 Articles